P/E ratio for Onconova Therapeutics (ONTX)
P/E ratio as of April 2024 (TTM): -0.9953
According to Onconova Therapeutics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.9953. At the end of 2022 the company had a P/E ratio of -0.7143.
P/E ratio history for Onconova Therapeutics from 2013 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -0.7143 | -72.83% |
| 2021 | -2.63 | -20.2% |
| 2020 | -3.29 | 2233.54% |
| 2019 | -0.1412 | -46.94% |
| 2018 | -0.2661 | -50.12% |
| 2017 | -0.5334 | 34.08% |
| 2016 | -0.3978 | -55.99% |
| 2015 | -0.9040 | -18.95% |
| 2014 | -1.12 | -63.99% |
| 2013 | -3.10 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Baxter BAX | 7.97 | -900.83% | 🇺🇸 USA |
 Spectrum Pharmaceuticals
SPPI | -2.86 | 187.46% | 🇺🇸 USA |
 CTI BioPharma
CTIC | -15.7 | 1,474.64% | 🇺🇸 USA |
 Cleveland BioLabs
CBLI | N/A | N/A | 🇺🇸 USA |
 Array Technologies ARRY | 23.6 | -2,469.96% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.